Singapore, June 17 -- Japanese pharma firm Eisai Co. has announced a strategic investment supported by the UK Government under the Life Sciences Innovative Manufacturing Fund (LSIMF), subject to terms and conditions, at its manufacturing site in Hatfield, Hertfordshire, United Kingdom (UK), to establish supply chain and packaging capabilities for current and future medicines that require cold-chain management, including lecanemab.

Published by HT Digital Content Services with permission from BioSpectrum Asia....